Banyu Pharmaceutical Co. Ltd

Merck + Co., Inc.

Msd K.k.

Yufu Sagara

Norikazu Otake

Akira Naya

Toshifumi Kimura

Takeru Yamakawa

Kazuhito Noguchi

Tomoshige Numazawa

Toru Fujikawa

Minaho Uchiyama

Yoshio Ogino

Teruyuki Nishimura

Masanori Asai

Kenji Matsuda

Noriaki Hashimoto

Miller J Ogidigben

Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity.  Rand Reach independently represent a lower alkyl group; Xrepresent a group of a formula (II-1): wherein:Rand Reach independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, Rand Rmay form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH), Rand Rmay form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

2-pyridinecarboxamide derivative having GK-activating effect

This invention relates to compounds which are represented by the general formula [I] [in which A stands for a group of the following formula [a] or [b]  The compounds of the invention exhibit selective antagonism to muscarinic Mreceptors, and therefore are useful as safe and effective agents showing little side effect, for treating diseases of the respiratory, urinary and digestive systems.

Amide derivatives

This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.

Ophthalmic compositions for treating ocular hypertension

This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I]  The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

Benzimidazolone derivatives

Growing community of inventors

Tsukuba, Japan

Yufu Sagara